Mitogen-activated protein kinase 12 (MAPK12) (MAPK12)

Mitogen-activated protein kinase 12 (MAPK12), commonly known as p38γ, is a member of the p38 mitogen-activated protein kinase family that acts as an essential component of signal transduction pathways [1.2.1, 1.3.1]. Unlike the ubiquitously expressed p38α and p38β isoforms, p38γ is highly expressed in skeletal muscle and plays a specialized role in myoblast differentiation and glucose metabolism [1.2.3, 1.4.2]. It is activated by environmental stresses and pro-inflammatory cytokines through a phosphorylation cascade involving MKK3 and MKK6 [1.3.3, 1.4.4]. In disease, p38γ is implicated in various cancers, including breast and colorectal cancer, where it can promote tumor progression, metastasis, and resistance to chemotherapy [1.3.1, 1.4.5]. It also plays a role in neurodegenerative diseases like Alzheimer's through the phosphorylation of Tau protein [1.3.1, 1.3.3]. While many classic p38 inhibitors, such as SB203580, do not effectively target p38γ, newer pan-p38 inhibitors like Doramapimod (BIRB 796) and isoform-specific compounds are being explored for their therapeutic potential [1.1.4, 1.3.1].

Other names

p38-gammaERK6SAPK3PRKM12Stress-activated protein kinase 3Extracellular signal-regulated kinase 6

Inhibition of the kinase activity of p38γ MAPK, typically through ATP-competitive or allosteric binding, to block downstream phosphorylation of substrates involved in stress response and inflammation.